Table 2.
Bispecific antibodies/BiTEs in development for MM
| Target | Agent | Type | Comments | Clinical trials no.* |
|---|---|---|---|---|
| BCMA | AMG 420 (BI 836909) | BiTE | 7 of 10 (70%) ORR in phase 1 expansion at MTD; single-agent phase 1b/2 ongoing | NCT02514239, NCT03836053 |
| BCMA | PF-06863135 | Bispecific | Single-agent phase 1 | NCT03269136 |
| BCMA | JNJ-64007957 | Bispecific | Single-agent phase 1 | NCT03145181 |
| BCMA | TNB-383B | Bispecific | Single-agent phase 1 | NCT03933735 |
| BCMA | REGN5458 | Bispecific | Single-agent phase 1 | NCT03761108 |
| BCMA | CC-93269 (EM901) | Bispecific | Single-agent phase 1 | NCT03486067 |
| BCMA | AMG 701 | Bispecific | Single-agent phase 1 | NCT03287908 |
| BCMA | AFM26 | Bispecific | CD16 × BCMA, targets NK cells, preclinical | |
| BCMA | HPN217 | Bispecific | Preclinical | |
| BCMA | EM801 | Bispecific | Preclinical | |
| CD38 | AMG 424 | Bispecific | Single-agent phase 1 | NCT03445663 |
| CD38 | GBR 1342 | Bispecific | Single-agent phase 1 | NCT03309111 |
| FcRH5 | BFCR4350A | Bispecific | Single-agent phase 1 | NCT03275103 |
| GPRC5D | JNJ-64407564 | Bispecific | Single-agent phase 1 | NCT03399799 |
ORR, overall response rate (partial response or better).
*
Search conducted on www.clinicaltials.gov on May 15, 2019.